Clinical Trial Update: A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) [Phase 3]

View source ↗

Summary

Phase 3 Velodrome trial update for the Port Delivery System delivering ranibizumab in neovascular age-related macular degeneration; the study is currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neovascular Age-related Macular Degeneration (nAMD) | Phase 3 | Status: ACTIVE_NOT_RECRUITING